Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

VJDementia is excited to bring you exclusive updates from the 17th Clinical Trials on Alzheimer's Disease (CTAD) conference, which took place in Madrid, Spain, from October 29 - November 01. This meeting brought together leading experts to discuss the latest clinical trial data to advance the treatment of Alzheimer's disease.

CTAD 2024

The 17th Clinical Trials on Alzheimer's Disease (CTAD) conference
29 Oct–01 November 2024 | Madrid, Spain

CTAD 2024

The 17th Clinical Trials on Alzheimer's Disease (CTAD) conference
29 Oct–01 November 2024 | Madrid, Spain
VJDementia is excited to bring you exclusive updates from the 17th Clinical Trials on Alzheimer's Disease (CTAD) conference, which took place in Madrid, Spain, from October 29 - November 01. This meeting brought together leading experts to discuss the latest clinical trial data to advance the treatment of Alzheimer's disease.
Challenges in developing anti-Aβ monoclonal antibodies for Alzheimer’s disease 1:54
Challenges in developing anti-Aβ monoclonal antibodies for Alzheimer’s disease
Lars Lannfelt • 31 Oct 2024
The development of lecanemab for the treatment of early Alzheimer’s disease 5:37
The development of lecanemab for the treatment of early Alzheimer’s disease
Lars Lannfelt • 31 Oct 2024
Measuring clinically relevant change in apathy symptoms in AD using data from the ADMET trials 1:20
Measuring clinically relevant change in apathy symptoms in AD using data from the ADMET trials
Krista Lanctôt • 29 Oct 2024
A study investigating nabilone for the treatment of agitation in AD 4:35
A study investigating nabilone for the treatment of agitation in AD
Krista Lanctôt • 29 Oct 2024
The value and limitations of p-tau217 in AD clinical trials 1:08
The value and limitations of p-tau217 in AD clinical trials
Todd Feaster • 29 Oct 2024
Advances in fluid biomarker research for the treatment of neurodegenerative diseases 4:48
Advances in fluid biomarker research for the treatment of neurodegenerative diseases
Suzanne Schindler • 12 Nov 2024
Advances in managing ARIA in patients with Alzheimer’s disease treated with donanemab 1:08
Advances in managing ARIA in patients with Alzheimer’s disease treated with donanemab
Suzanne Schindler • 12 Aug 2024
Recommendations for the appropriate use of donanemab in Alzheimer’s disease 1:30
Recommendations for the appropriate use of donanemab in Alzheimer’s disease
Suzanne Schindler • 12 Aug 2024
Swedish BioFINDER-2: investigating the diagnostic accuracy of p-tau217 for Alzheimer’s disease 1:07
Swedish BioFINDER-2: investigating the diagnostic accuracy of p-tau217 for Alzheimer’s disease
Suzanne Schindler • 12 Aug 2024
The great debate: defining AD beyond amyloid-β 4:42
The great debate: defining AD beyond amyloid-β
Nicolas Villain • 8 Nov 2024
PreventE4: evaluating the role of omega-3 in cognitive health and Alzheimer’s disease 4:42
PreventE4: evaluating the role of omega-3 in cognitive health and Alzheimer’s disease
Hussein Yassine • 11 Nov 2024
CS6253: a novel peptide with the potential to lower the risk of Alzheimer’s disease 3:13
CS6253: a novel peptide with the potential to lower the risk of Alzheimer’s disease
Hussein Yassine • 11 Nov 2024
Novel therapeutics being explored in AD and moving towards combination approaches 1:55
Novel therapeutics being explored in AD and moving towards combination approaches
Charbel Moussa • 6 Nov 2024
Tyrosine kinase inhibitors in neurodegenerative diseases and lessons learned from cancer treatment 3:09
Tyrosine kinase inhibitors in neurodegenerative diseases and lessons learned from cancer treatment
Charbel Moussa • 6 Nov 2024
Understanding agitation in Alzheimer’s disease and current approaches to management 3:31
Understanding agitation in Alzheimer’s disease and current approaches to management
Krista Lanctôt • 29 Oct 2024
The International Working Group’s new recommendations for diagnosing AD 6:25
The International Working Group’s new recommendations for diagnosing AD
Nicolas Villain • 8 Nov 2024
The content of VJDementia is intended for healthcare professionals